Panel firm offers speedy trend analysis

All Global, a Kantar-owned provider of healthcare panel data, has launched a service designed to offer, within 24 hours, analyzed responses to breaking drug news.
The service, Snapshot, can generate sample sizes in the hundreds across six countries, according to a release. For example, within hours of the FDA's decision to severely restrict use of GlaxoSmithKline diabetes pill Avandia, Snapshot closed a survey of 100 UK diabetes specialists and endocrinologists, with 63% saying the news would encourage their use of a DPP 4 inhibitor/GLP 1 mimetic, 12% saying they would initiate insulin earlier, and 13% saying they would not change Rx habits.
Release of FDA ad-com briefing documents for weight-loss candidate Qnexa prompted a Snapshot survey of 730 US PCPs, with 82% saying they would recommend approval. In a follow-up survey of 398 PCPs after the ad-com voted 10-6 against approval, 68% said they would have recommended approval.
You must be a registered member of MMM to post a comment.

Next Article in Features

Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.

Email Newsletters